A significant breakthrough in cancer research is emerging with the use of mini-antibodies to re-engage dysfunctional p53. This essential malignant inhibitor protein is frequently disabled in several kinds of cancer, https://reallivesocial.com/story7658473/mini-antibodies-revive-the-p53-protein-the-new-pathway-for-malignant-therapy